Embecta Corp.
EMBC • NASDAQ
Embecta Corp. is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Devdatt Kurdikar, with a market cap of $619.9M.
CEODevdatt Kurdikar
Market Cap$619.9M
Drug Manufacturers - Specialty & Generic
Healthcare
Employees2.2K
Websiteembecta.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Embecta Corp.
Date
Friday, May 8, 2026 (in 3 months)
Timing
Before Market Open (6:00 AM New York)
Fiscal Period
Q2 2026
EPS Estimate
$0.67
Revenue Estimate
$255.5M
Earnings History
Past 12 earnings reports for Embecta Corp.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 5, 2026 | Q1 2026 | $0.71Est: $0.67 | +6.0% | $261.2MEst: $258.1M | +1.2% |  10-Q |
| Nov 25, 2025 | Q4 2025 | $0.50Est: $0.46 | +8.7% | $264.0MEst: $265.7M | -0.6% | 10-K |
| Aug 8, 2025 | Q3 2025 | $1.12Est: $0.78 | +43.6% | $295.5MEst: $278.2M | +6.2% | 10-Q |
| May 9, 2025 | Q2 2025 | $0.70Est: $0.59 | +18.6% | $259.0MEst: $261.8M | -1.1% | 10-Q |
| Feb 6, 2025 | Q1 2025 | $0.65Est: $0.44 | +47.7% | $261.9MEst: $256.1M | +2.3% | 10-Q |
| Nov 26, 2024 | Q4 2024 | $0.45Est: $0.36 | +25.0% | $286.1MEst: $276.9M | +3.3% | 10-K |
| Aug 9, 2024 | Q3 2024 | $0.74Est: $0.46 | +60.9% | $272.5MEst: $267.4M | +1.9% | 10-Q |
| May 9, 2024 | Q2 2024 | $0.67Est: $0.40 | +67.5% | $287.2MEst: $264.7M | +8.5% | 10-Q |
| Feb 9, 2024 | Q1 2024 | $0.61Est: $0.46 | +32.6% | $277.3MEst: $264.9M | +4.7% | 10-Q |
| Nov 21, 2023 | Q4 2023 | $0.59Est: $0.40 | +47.5% | $281.9MEst: $271.6M | +3.8% | — |
| Aug 8, 2023 | Q3 2023 | $0.69Est: $0.46 | +50.0% | $286.1MEst: $275.0M | +4.1% | — |
| May 12, 2023 | Q2 2023 | $0.75Est: $0.49 | +53.1% | $277.1MEst: $262.9M | +5.4% | — |